UroGen (URGN) Director Equity Grants — 10,000 Options; 8,000 RSUs

Rhea-AI Filing Summary

UroGen Pharma Ltd. (URGN) director James A. Robinson Jr. reported grants on 08/26/2025 consisting of a stock option and restricted stock units. The stock option is a right to buy 10,000 ordinary shares at an exercise price of $19.50 per share, exercisable through 08/26/2035. The RSUs represent a contingent right to 8,000 ordinary shares. Both the option shares and RSU shares vest in equal quarterly installments over one year, subject to the director's continuous service under the 2017 Equity Incentive Plan. The Form 4 was signed by an attorney-in-fact on 08/27/2025.

Positive

• 10,000 stock options granted at an exercise price of $19.50, providing potential upside if share price rises
• 8,000 RSUs granted, each representing a contingent right to one ordinary share
• Vesting schedule is specified: equal quarterly installments over one year, tied to continuous service under the 2017 Equity Incentive Plan
• Direct ownership recorded post-grant: 10,000 option shares and 8,000 RSUs reported as direct holdings

Negative

• None.

Insights

Corporate Governance Expert

TL;DR Director received equity grants (10,000 options, 8,000 RSUs) with one-year quarterly vesting to align long-term incentives.

The filing documents routine director compensation rather than a change in control or unusual transaction. The option has a stated $19.50 exercise price and 10-year contractual life to 08/26/2035. Vesting occurs in equal quarterly installments over one year for both awards, conditioned on continuous service under the 2017 Equity Incentive Plan. This is consistent with board retention practices and does not itself disclose additional terms such as acceleration or tax treatment.

Securities/Compensation Analyst

TL;DR Grants are standard equity-based compensation disclosures with clear quantities, price, and vesting schedule.

The Form 4 provides exact grant amounts and vesting mechanics: 10,000 option shares at $19.50 and 8,000 RSUs, both vesting quarterly over one year. The document shows direct ownership post-grant of 10,000 option shares and 8,000 RSUs. No additional derivative holdings, dispositions, or unusual arrangements are reported. The filing does not state impact on total outstanding shares or dilution metrics.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Robinson James A. Jr.

(Last) (First) (Middle)

400 ALEXANDER PARK DRIVE

(Street)

PRINCETON NJ 08540

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
UroGen Pharma Ltd. [ URGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right ot buy)	$19.5	08/26/2025		A		10,000		(1)	08/26/2035	Ordinary Shares	10,000	$0	10,000	D
Restricted Stock Unit	(2)	08/26/2025		A		8,000		(3)	(3)	Ordinary Shares	8,000	$0	8,000	D

Explanation of Responses:

1. The shares underlying the stock option will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates.

2. Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.

3. The shares underlying the RSUs will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates.

	/s/ Jason D. Smith, Attorney-in-Fact	08/27/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did URGN director James A. Robinson Jr. receive on 08/26/2025?

He received a stock option for 10,000 ordinary shares at an exercise price of $19.50 and 8,000 restricted stock units (RSUs) on 08/26/2025.

When do the granted options and RSUs vest according to the Form 4 for URGN?

Both the stock option and the RSUs vest in equal quarterly installments over one year, subject to the director's continuous service under the 2017 Equity Incentive Plan.

What is the exercise period or expiration date for the stock option reported by URGN director?

The stock option has an expiration date of 08/26/2035, giving a 10-year contractual life from the grant date.

How many shares does the Form 4 show the reporting person beneficially owning after the transaction?

The Form 4 reports beneficial ownership following the transaction as 10,000 option shares and 8,000 RSUs held directly.

Who signed the Form 4 filed for URGN and when was it signed?

The Form 4 was signed by Jason D. Smith, Attorney-in-Fact on 08/27/2025.